Behcet's disease

Clinical and Experimental Medicine

Volumn 4, Issue 3, 2004, Pages 103-131

  Al Mutawa, S A ^a,b   Hegab, S M ^c  

^a Al Bahar Eye Center ^*  (Kuwait)

^b Al Bahar Eye Center   (Kuwait)

^c Uveitis and External Disease Clinic   (Kuwait)

Author keywords

Behcet's disease; HLA antigen; Immunosuppressant; Ocular Behcet's; Pathergy

Indexed keywords

ALEMTUZUMAB; ALLOPURINOL; ALPHA INTERFERON; AUTOANTIGEN; AZATHIOPRINE; CELL ADHESION MOLECULE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; HLA B ANTIGEN; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4 RECEPTOR; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; METHOTREXATE; RETINA S ANTIGEN; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIGEN ANTIBODY REACTION; B LYMPHOCYTE; BEHCET DISEASE; CELL ACTIVITY; CELL INFILTRATION; CLINICAL FEATURE; GENITAL ULCER; HUMAN; INFLAMMATION; MORBIDITY; MORTALITY; MOUTH ULCER; NEPHROTOXICITY; NEUTROPHIL; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; REVIEW; TH1 CELL; TH2 CELL; UVEITIS; VASCULITIS;

BEHCET SYNDROME; HUMANS;

EID: 11944273987     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-004-0045-0     Document Type: Review

References (490)

1. Michealson JB, Chisari FV (1982) Behcet's disease. Surv Ophthalmol 20:189-20
2. Hamza M, Ayed K, Ben-Ayed H (1986) Malasie de Bahcet. In: Khan MF, Peltier Ap (eds) Maladie systemique. Flammarion, Paris, pp 668-686
3. Opremcak EM (1994) Uveitis. A clinical manual for ocular inflammation. Springer Verlag, New York Berlin Heidelberg, pp 200-202
4. George RK, Chan CC, Whitcup SM, Nussenblatt RB (1997) Ocular immunopathology of Behcet's disease. Surv Ophthalmol 42:157-162
5. Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behcet's disease. N Engl J Med 341:1284-1291
6. Feigenbaum A, Kornbluth W (1946) Behcet's disease as a manifestation of a chronic septic condition connected with a constitutional disorder. Acta Med Orient Jerusalem 5:139
7. Mason RM, Barnes CG (1969) Behcet's syndrome with arthritis. Ann Rheum Dis 28:95-103
8. Yardakul S, Yazici H, Tuzun Y et al (1983) The arthritis of Behcet's disease. A prospective study. Ann Rheum Dis 42:505
9. Yazici H, Tuzolaci M, Yardakul S (1981) A controlled survey of sacroiliitis in Behcet's disease. Ann Rheum Dis 40:558
10. Ballatyne AJ, Michealson IC (1962) Textbook of the fundus of the eye. Williams and Wilkins, Baltimore, pp 198-199
11. Hills EA (1967) Behcet's syndrome with aortic aneurysms. BMJ 4:152
12. Cucuob P, Sbai A, Wechsler B, Brocherion I, Braesco J, Kieffer E, Piette JC (2000) Vascular manifestations of Behcet's syndrome associated with solitary ulcerations and resolved with immunosuppressants. Rev Med Intern 21:353-357
13. Braverman IM (1981) Skin signs of systemic disease. 3rd edn. Philadelphia, pp 366-368
14. Plotkin GR (1988) Miscellaneous clinical manifestations: gastro-intestinal,hepatic, splenic, pancreatic, genitourinary, and dermatologic features. In: Plotkin GR, Calabro JJ, O'Duffy JD (eds) Behcet's disease: a contemporary synopsis. Futura Publishing, N.Y., p 239
15. Afifi AK, Frayha RA,Tekian A (1980) The myopathy of Behcet's disease - a histological light and electron microscopic study. J Neurol Sci 48:333
16. Farah S, Al-Shubaili A, Montaser A et al (1998) Behcet's syndrome: a report of 41 patients with emphasis on neurological manifestations - short report. J Neurol Neurosurg Psychiatry 64:382-384
17. Mousa AA, Maarafie AA, AlRifai KM, Dajani AI, Mukhtar MM (1986) Behcet's disease in Kuwait, Arabia - a report of 29 cases and review. Scand J Rheumatol 15:310-332
18. Orsson PJ (1980) Behcet's syndrome. N Engl J Med 302:407
19. Duarte M, Solans R, Gomez A, Garcia-Alfranca F et al (1998) Diffuse proliferative glomerulonephritis in Behcet's syndrome (letter). Br J Rheumatol 37:466-467
20. Sigel N, Earson R (1965) Behcet's syndrome: a case with benign pericarditis and recurrent neurologic involvement treated with adrenal steroids. Arch Intern Med 115:302
21. Salvin RE, de Grant WJ (1981) Pathology of the lung in Behcet's disease case report and review of the literature. Am J Surg Pathol 5:799
22. Davies JD (1973) Behcet's syndrome with haemoptysis and pulmonary lesions. J Pathol 109:351
23. Friegenbaum A (1956) Description of Behcet's syndrome in the Hippocratic Third Book of Endemic Diseases. Br J Ophthalmol 28:516-521
24. Shigeta T (1924) Recurrent iritis hypopyon and its pathological significance. Acta Soc Jpn 28:516-521
25. Adamantiadis B (1931) Sur un cas d'iritis a recidevante. Ann Ocul 168:271-274
26. Whitwell GPB (1934) Recurrent buccal and vulvular ulcers with associated embolic phenomena in skin and eye. Br J Dermatol 46:414-419
27. Behcet H (1937) Uber rezideivvierende aphthose, durch ein virus verusachte gasch wure am MUND, am auge und an genitalien. Dermatol Wochenschr 105:1152-1157
28. Behcet H (1937) Considerations sur les lesions aphteuse de la bouche et de la parties genitales ainsi que sur les manifestations oculaire d'origin penzent virutique et observation cosernant leur foyer d'infection. Arch Dermatol Suvniligr 23-24:1521-1529
29. Behcet H (1940) Some observations on the clinical picture of the so called triple symptom complex. Dermatologica 81:73-76
30. Bluthe L (1908) Zur Erkenntnis des rezidivierenden Hypopyons. Strauss, Heidelberg
31. Gilbert TW (1921) Uber den pathol-anat. Befund bei Iridocyklitis septica. Arch Augenheilk 87:27
32. Nakayama N (1926) Pathological anatomy of the so-called recurring hypopyon uveitis. Albrecht v Graefes Arch Ophthal 116:249
33. Zouboulis CC, Diawari D, Kirch W, Ochsendorf FR et al (1966) Adamantiadis-Behcet's disease in Germany: data of the German registry in 1966. Revue du Rhumatisme "English Edition" 63:538
34. AlDalaan A, AlBalla S, AlSukait M, Bahabri S, Mousa M, Biyari T (1996) The prevalence of Behcet's disease in Al Qassim region of Saudi Arabia. Rev Rhum 63:539
35. Shahrami F, Davatchin F, Akbarian M et al (1996) The 1996 survey of Behcet's disease in Iran, study of 3153 cases. Rev Rhum 63:536
36. Davatchi F, Sharam F, Akbarian M, Hatef MR, Chams C (1992) In: Nasution AR, Darmawan J, Isbago H (eds) Proceedings of the 7th APLAR Congress of Rheumatology. Churchill Livingstone, Japan 95:8
37. Dilsen N (1996) History and development of Behcet's disease. VII. International Conference on Behcet's Diease. Rev Rhum 63:512-519
38. Chajek T, Fainaru M (1975) Report of 41 cases and review of literature. Medicine (Baltimore) 54:179
39. Seaman G, Perace RA (1996) Disease manifestations in a population drawn from the UK Behcet's Syndrome Society. VIIth International Conference on Behcet's Disease. Rev Rhum 63:539
40. Shimizu T, Erlich GE, Inaba G, Hayashi K (1979) Behcet's disease (Behcet's syndrome). Semin Arthritis Rheum 8:223-260
41. Shimizu K (1970) Fluorescein fundus angiography in Behcet's sundrome Nippon Ganku Gakkai Zasshi 74:1432-1448
42. Perkins ES (1961) Uveitis and toxoplasmosis. Little Brown, Boston p 119
43. Rodriguez A, Margarita C, Pedroza-Seres M et al (1996) Referral patterns of uveitis in a tertiary eye care center. Epidemiology and biostatistics. Arch Ophthalmol 114:593-599
44. Moutsopoulos HM (1994) Behcet's syndrome. In: Isselbacher J, Braunwald E, Wilson D, Martin B, Fauci A, Kasper D (eds) Harrison's principles of internal medicine. Mc-Graw Hill, New York, pp 1669-1670
45. Oniki S (1974) Pathogenesis and treatment of Behcet's disease. Acta Soc Ophthalnol Jpn 78:1347
46. Yazici H, Tuzun Y, Pazarli H et al (1984) Influence of age and patient's sex on the prevalence and severity of manifestations of Behcet's syndrome. Ann Rheum Dis 43:783-789
47. Ohno S (1986) Behcet's disease in the world. In: Lehner T, Barnes CG (eds) Recent advances in Behcet's disease. Royal Society of Medicine Services, London
48. Lang BA, Laxer RM, Thorner P, Greenberg M, Sylverman E (1990) Pediatric onset of Behcet's syndrome with myositis: case report and literature review illustrating unusual features. Arthritis Rheum 33:418-425
49. Duffr JD, Goldstein NP (1976) Neurologic involvement in 7 patients with Behcet's disease. Am J Med 61:170
50. Goolamali SK, Comaish JS, Hassanyeh F, Stephens (1976) Familial Behcet's syndrome. Br J Dermatol 95:637-642
51. Vaiopoulos G, Sfikakis PP, Hatzinicolaou P, Stamatelos G, Kaklamanis P (1996) Adamantiades-Behcet's disease in sisters. Clin Rheumatol 15: 382-384
52. Woodrow JC, Graham DR, Evans CC (1990) Behcet's syndrome in HLA-identical siblings. Br J Rheumatol 29:225-227
53. Kone-Paut I, Yurdakul S, Bahabri S, Shafae N, Ozen S, Ozdogan H, Louis-Bernard J (1998) Clinical features of Behcet's disease in children: an international collaborative study of 86 cases. J Pediatr 132:721-725
54. Fresco I, Soy M, Hamuryudan V, Yurdakul S, Yuvuz S, Tumer Z, Yazici H (1998) Genetic anticipation in Behcet's syndrome. Ann Rheum Dis 57:45-48
55. The International Study Group for Behcet's Disease (1992) Evaluation of diagnostic (classification) criteria in Behcet's disease - towards internationally agreed criteria. Br J Rheumatol 31:299-308
56. Behcet's Disease Research Committee of Japan 1972, Quoted by Shimizu T (1974) Behcet's disease: guide to diagnosis of Behcet's disease. Jpn J Ophthalmol 18:291-294
57. O'Duffy JD (1974) Criteres proposes pour le diagnostic de la maladie de Behcet - et notes therapeutiques. Rev Med 36:2371-2379
58. Zhang X-Q (in Chinese) (1980) Chin J Intern Med 19:15
59. Dilsen N, Konice M, Aral O (1986) Our diagnostic criteria for Behcet's disease. In: Lehner T, Barnes CG (eds) Recent Advances in Behcet's Disease. Royal Society of Medicine Services. Int Congr Sympos Series 103:177-180
60. James DG (1986) Behcet's disease. In: Fitzpatrick TB, Eizen AZ, Wolff K, Freedberg I, Austin KF (eds) Dermatology in general medicine. McGraw-Hill, New York, pp 1242
61. Barnes CG (1999) Behcet's syndrome-classification criteria (review). Ann Med Interne (Paris) 150:477-482
62. Ozen S (1999) Vasculopathy, Behcet's syndrome and familial Mediterranean fever (Review). Curr Opin Rheumatol 11:393-398
63. Tune R, Uluhan A, Melikoglu M, Ozyagan Y, Ozdagan H, Yazici H (2001) A reassessment of the International Study Group criteria for the diagnosis (classification) of Behcet's syndrome. Clin Exp Rheumatol 19[Suppl 24]:S45-S47
64. Behcet's Disease Research Committee of Japan 1972, quoted by Shimizu T (1979) Clinicopathological studies on Behcet's disease. In: Dilsen N, Konice M, Ovul C (eds) Behcet's disease. Excerpta Med Int Congr Series 467:9-43
65. Mizushima Y (1988) Recent research into Behcet's disease in Japan. Int J Tissue React 10:59-65
66. Ben-Ezra D (1991) The ocular viewpoint of Behcet's disease. In: O'Duffy JD, Kokman F (eds) Behcet's disease. Basic and clinical aspects. Dekker, New York, pp 93-97
67. Ben-Ezra (1980) Diseases of the choroid and anterior uvea. In: Michaelson IC (ed) Textbook of the fundus of the eye, 3rd edition. Churchill Livingstone, Edinburgh, pp 708-712
68. Ben-Ezra D, Cohen E (1986) Treatment and visual prognosis in Behcet's disease. Br J Ophthalmol 70:589-592
69. Ben-Ezra D (1989) Treatment of Behcet's disease. Autoimmunity Forum. Ophthalmology 1:1-4
70. Tunc R, Keyman E, Melikoglu M, Yazici H (2002) Target organ association in Turkish patients with Behcet's disease: a cross sectional study by exploratory factor analysis. J Rheumatol 29:2392-2396
71. Koc Y, Gull I, Akpek G et al (1992) Vascular involvement in Behcet's disease. J Rheumatol 19:402-410
72. Dimiralp E, Mat C, Hamuryudan V, Yurdakul S, Hizli N, Yazici H (2001) Papulopustular skin lesions are seen more frequently in patients with Behcet's syndrome who have arthritis: controlled and masked study. Ann Rheum Dis 60:1074-1076
73. Krause L, Leibovici L, Guedj D, Molad Y, Weinberger A (1999) Disease patterns of patients with Behcet's disease demonstrated by factor analysis. Clin Exp Rheumatol 17:347-350
74. Hegab S, Al Mutawa S (2000) Immunopathogenesis of Behcet's disease. Clinical Immunol 96:174-186
75. Chamberlain MA, Cooper C, Yazici H, Sharp H, Barker DJP (1991) Risk factors for Behcet's disease in Britain and Turkey. In: O'Duffy JD, Kokmen E (eds) Behcet's disease. Basic and clinical aspects. Dekker, New York, pp 3-9
76. Sezer FN (1956) Further investigations on the virus of Behcet's disease. Am J Ophthalmol 41:41
77. Nakagawa Y, Shingu M (1958) Studies on the pathogenic agent of Behcet's disease. 1. The isolation of Behcet's disease virus on the chorio-allantois of developing chick embryos. J Jpn Assoc Infect Dis 32:270
78. Kozousek V, Jandasek L (1958) Behcet's disease. Cesk Oftalmol 14:260
79. Zeavin BH, King MJ, Gohd RS (1956) A case of Behcet's disease. Am J Ophthalmol 41:55
80. Thygeson P, Hogan MJ, Kimura SJ (1957) Observations on uveitis associated with viral disease. Trans Am Ophthalmol Soc 55:333
81. Lehner T (1969) Pathology of recurrent oral ulcerations and oral ulcerations in Behcet's syndrome: light, electron and fluorescence microscopy. J Pathol 97:481-494
82. Lee ES, Lee S (1996) Herpes virus detection by polymerase chain reaction in intestinal ulcers of patients with Behcet's disease (Abstract). Rev Rhum 63:533
83. Bang D, Cho YLT, Lee S, Sohn S, Lee ES (1996) Detection of herpes simplex virus DNA by polymerase chain reaction in genital ulcers of patients with Behcet's disease (Abstract). Rev Rhum 63:62
84. Eglin RP, Lehner T, Subak-Sharpe JH (1982) Detection of RNA complementary to herpes simplex virus in mononuclear cells from patients with Behcet's syndrome and recurrent oral ulcers. Lancet II:1356-1361
85. Lee S, Bang D, Cho YH, Lee ES, Sohn S (1996) Polymerase chain reaction reveals herpes simplex virus DNA of patients with Behcet's disease. Arch Dermatol Res 288:179-183
86. Sohn S, Lee ES, Bang D, Lee S (1998) Behcet's disease-like symptoms induced by Herpes simplex virus in ICR mice. Eur J Dermatol 8:21-23
87. Nakagawa H, Harrison LC (1996) The potential role of retrovirus in autoimmunity. Immunol Rev 152:193-236
88. Guillevin L (1999) Virus-associated vasculitis. Rheumatology 38:588-590
89. Mc-Inetosh RS, Huggins ML, Kontogiannis V, Tigle PJ, Bowell R (2001) Retroviral activity in Behcet's syndrome and systemic lupus erythematosus detected by a PCR-based reverse transcriptase assay. Rheumatol Int 21:53-57
90. Kiraz S, Ertenli I, Benekli M, Calguneri M (1996) Parvovirus B19 infection in Behcet's disease. Clin Exp Rheumatol 14:71-73
91. Cantini F, Emmi L, Niccoli L, Padula A, Salvarani C, Olivier I (1997) Lack of association between chronic hepatitis C virus infection and Behcet's disease. Clin Exp Rheumatol 15:338-339
92. Cooper C, Pippard EC, Sharp H, Wickham C, Chamberlain MA, Barker DJP (1989) Is Behcet's disease triggered by childhood infection. Ann Rheum Dis 48:421-423
93. Aoki K, Ohno S (1972) Studies on the constitution and past history of patients with Behcet's disease. Acta Soc Ophthalmol Jpn 76:1608-1612
94. Narikawa S, Suzuki Y, Takahashi M, Furukawa A, Sakane T, Mizushima Y (1995) Streptococcus oralis previously identified as uncommon Streptococcus sanguis in Behcet's disease. Arch Oral Biol 40:685-690
95. Lehner T, Lavery E, Smith R, vander zee R, Mizushima Y, Shinnick T (1991) Association between the 65-kilodalton heat shock protein, Streptococcus sanguis and the corresponding antibodies in Behcet's syndrome. Infect Immun 59:1434-1441
96. Pervin K, Childerstone A, Shinnick T et al (1993) T-cell epitope expression of mycobacterial and homologous 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet's disease. J Immunol 151:2273-2282
97. Direskeneli H, Hasan A, Shinnick T et al (1996) Recognition of B-cell epitopes of the 65KD HSP in Behcet's disease. J Immunol 43:464-471
98. Kaneko S, Suzuki N, Yamashita N, Nagafuchi H, Nakajima T, Wakisaka S (1997) Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behcet's disease (BD) in Japan. Clin Exp Immunol 108:204-212
99. Direskeneli H, Eksioglu-Demiralp E, Yavuz S et al (2000) T cell responses to 60/65 kDa heat shock protein derived peptides in Turkish patients with Behcet's disease. J Rheumatol 27:708-713
100. Yamaguchi H, Taguchi H, Katura T, Kumada J, Uekesa T, Ogata S (1989) Purification of cross protein antigen shared by Yersinia enterocolitica and other gram-negative bacteria with monoclonal antibody. Microbiol Immunol 33:683-688
101. Yamaguchi H, Yamamoto T, Taguchi H, Ogata S (1990) Yersinia enterocolitica immunodominant 60kDa antigen, common to a broad range of bacteria, is a heat shock protein. J Gen Microbiol 136:1091-1097
102. Albani S, Tuckwell JE, Esparza L, Carson DA, Roudier J (1992) The susceptibility sequence to rheumatoid arthritis is a cross-reactive B cell epitope shared by the Escherichia coli, heat-shock protein dnaj and the histocompatibility leucocyte antigen DRB10401 molecule. J Clin Invest 89:827-831
103. Jindal S, Dudani AK, Singh B, Harley CB, Gupta RS (1989) Primary structure of human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol 9:2279-2283
104. Tanaka T, Yamakawa N, Okada A et al (1996) Common antigenicity between Yersinia enterocolitica-derived heat shock protein and the retina, and its role in uveitis. Ophthalmic Res 28:284-288
105. Hu W, Hasan A, Wilson A et al (1998) Experimental induction of uveitis with 60-kD a heat shock protein-derived peptide 336-351. Eur J Immunol 28:2444-2455
106. Ohno S, Aoki K, Sugiura S, Nakayama E, Itakura K, Aizawa M (1973) HLA-A5 and Behcet's disease. Lancet II:1383
107. O'Duffy JD, Kokmen E (eds) (1991) Microbial etiology Behcet's disease. Basic and clinical apects. Dekker, New York, pp 395-461
108. Mizuki N, Ohno S, Sugimura K et al (1992) Association of HLA-B51 and lack of association of class II alleles with Behcet's disease. Tissue Antigens 40:22-30
109. Chung YM, Tsai ST, Liao F, Liu JH (1987) A genetic study of Behcet's disease in Taiwanese Chinese. Tissue Antigens 30:68
110. Ohno S (1986) Immunogenetic studies on ocular diseases. In: Blodi F et al (eds) Acta XXV Concilium Ophthalmologicum. Kluger & Ghedini, Amsterdam, pp 144-154
111. Chajek-Shaul T, Pisanty S, Knobler H et al (1987) HLA-B51 may serve as an immunogenetic marker for a subgroup of patients with Behcet's syndrome. Am J Med 83:666
112. Arber N, Klein T, Meiner Z, Pras E, Weinberger A (1991) Close association of HLA-B51 and B52 in Israeli patients with Behcet's syndrome. Ann Rheum 50:351-353
113. Yazici H, Tuzun Y, Pazarli H, Yalcin B, Yurdakul S, Muftuoglu A (1980) The combined use of HLA-B5 and the pathergy test as diagnostic markers of Behcet's disease in Turkey. J Rheumatol 7:206
114. Zervas J, Vavopoulus G, Sakellaropoulus N, Kaklamanis PH, Fessan PH (1988) HLA antigens and adamantiades-Behcet's disease (A-BD) in Greeks. Clin Exp Rheumatol 6:277
115. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M (1982) Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol 100:1445
116. Mizushima Y (1988) Recent research into Behcet's disease in Japan. Int J Tissue React 10:59
117. O'Duffy JD, Taswell HF, Elveback LR (1974) HLA antigens in Behcet's disease. J Rheumatol 3:1
118. Chamberlain MA (1977) Behcet's syndrome in 32 patients in Yorkshire. Ann Rheum Dis 36:491
119. Lehner T, Batchelor JR, Challacombe SJ, Kennedy L (1979) An immunogenetic basis for the tissue involvement in Behcet's syndrome. Immunology 37:895-900
120. Ohno S, Char DH, Kimura SJ, O'Connor GR (1978) Studies on HLA antigens in American patients with Behcet's disease. Jpn J Ophthalmol 22:58-61
121. Moore SB, O'Duffy JD (1986) Lack of association between Behcet's disease and major histocompatibility complex II antigens in an ethnically diverse North American Caucasoid patient group. J Rheumatol 13:771-773
122. Foster CS, Baer J (1992) Behcet's disease in America: ocular manifestations and response to treatment. In: Dernouchamps JP, Verougstraete C, Caspers-Velu, Tassignon MJ (eds) Recent advances in uveitis. Proceedings of the Third International Symposium on Uveitis, Brussels, Belgium, May 24-27. Kugler, Amsterdam, pp 185-189
123. Collum LMT, Mullaney J, Bowell R (1981) Current concepts of Behcet's disease. Trans Ophthalmol Soc UK 101:422-428
124. Jankowski J, Crombie I, Jankowski R (1992) Behcet's syndrome in Scotland. Postgrad Med J 68:566-570
125. Zouboulis CC, Buttner P, Djawari D et al (1993) HLA-muster bei morbus Adamantiades-Behcet in Deutschland. Hautarzt 44:81-5
126. Zierhut M, Saal J, Pleyer U, Kotter I, Durk H, Fierlbleck G (1995) Behcet's disease: epidemiology and eye manifestations in German and Mediterranean patients. Ger J Ophthalmol 4:246-251
127. Soylu M, Ersoz TR, Erken E (1992) The association between HLA B5 and ocular involvement in Behcet's disease in southern Turkey. Acta Ophthalmol (Copenh) 70:786-789
128. Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomata H, Nose Y (1995) Prognostic factors of vision in patients with Behcet's disease. Ophthalmology 102:317-321
129. Cocherau-Massin I,Wechsler B, Le Hoang P, Le Thi Huong Du, Girard B, Rousselie F et al (1992) Ocular prognosis in Behcet's disease. J Fr Ophthalmol 15:343-347
130. Kim MS, Kim JH (1989) Prognostic comparison of Behcet's disease with or without HLA-Bw51 antigen. Korean J Ophthalmol 3:85-89
131. Weinberg RS (1992) Selected inflammatory diseases of the skin and eye. Ophthalmol Clin North Am 5:215-216
132. Michelson JB, Friedlander MH (1990) Behcet's disease. Int Ophthalmol Clin 30:271
133. Kaya TI, Dur H, Tersen U, Gurler A (2002) Association of class I HLA antigens with the clinical manifestations of Turkish patients with Behcet's disease. Clin Exp Dermatol 27:498-501
134. Lehner T, Welsh KL, Batchelor JR (1981) The relationship of HLA phenotype to immunoglobulin present in immune complexes from patients with Behcet's syndrome. Tissue Antigens 17:357-361
135. Kilmartin DJ, Finch A, Acherson RW (1997) Primary association of HLA B51 with Behcet's disease in Ireland. Br J Ophthalmol 81:649-653
136. Mizuki N, Inoko H, Ando H et al (1993) Behcet's disease associated with one of the HLA-B51 subantigens. HLA-B5101. Am J Ophthalmol 16:406-409
137. Sanz L, Gonzalez-Escribano F, Pablo R de, Nunez-Roldan A, Kreisler M, Vilches C (1998) HLA-Cw1602: a new susceptibility marker of Behcet's disease in Southern Spain. Tissue Antigens 51:111-114
138. Vilche, Bunce M, de Pablo R, Murray AK, McIntyre CA, Kreisler M (1997) Complete cooling regions of two novel HLA-alleles detected by phototyping (PCR-SSP) in British Caucasoid population: B*5108 and 5002. Tissue Antigens 50:38-41
139. Mizuki N, Ota M, Katsuyama Y et al (2002) Sequencing-based typing of HLA-B*51 alleles and the significant association of HLA-B*5105 and -B*5108 with Behcet's disease in Greek patients. Tissue Antigens 59:118-121
140. Kera J, Mizuki N, Ota M et al (2000) Significant association of HLA-B*5101, B*5108, lack of association of class II alleles with Behcet's disease in Italian patients. Tissue Antigens 54:565-571
141. Yabuki K, Ohno S, Mizuki N et al (1999) HLA class I, class II typing of the patients with Behcet's disease in Saudi Arabia. Tissue Antigens 54:273-277
142. Mizuki N, Ota M, Katsuyama Y et al (2001) HLA class I genotyping including HLA-B51 allele typing in the Iranian patients with Behcet's disease. Tissue Antigens 57:457-462
143. Mizuki N, Ota M, Katsuyama Y et al (2001) HLA-B*51 allele analysis by PCR-SBT method, a strong association of HLA-B*5101 with Japanese patients with Behcet's disease. Tissue Antigens 58:181-184
144. Saper MA, Bjorkman PJ, Wiley DC (1991) Refined structure of human histocompatibility antigen HLA-A2 at 2.6 A resolution. J Mol Biol 219:277-319
145. Mizuki N, Ota M, Katsuyama Y et al (2000) Localisation of the pathogenic gene of Behcet's disease onto the HLA-B locus by investigation of microsatellite polymorphism in three different populations. Invest Ophthalmol Vis Sci 41:3702-3708
146. Gul A, Hajeer A, Worthington J, Barrett J, Ollier W, Silman A (2001) Evidence for linkage of the HLA-B locus in Behcet's disease, obtained using the transmission disequilibrium test Arthritis Rheum 44:239-241
147. Ota M, Mizuki N, Katsuyama Y et al (1999) The critical region for Behcet's disease in the human major histocompatibility complex is reduced to a 46-kb centromeric of HLA-B, association analysis using refined microsatellite mapping. Am J Hum Genet 64:1406-1410
148. Mizuku N, Ota M, Katsuyama Y et al (1999) Association analysis between the MICA-A and HLA-B alleles in Japanese patients with Behcet's disease. Arthritis Rheum 42:1961-1966
149. Shina T, Tamiya G, Oka A, Takishima N, Inoko H (1999) Genome sequencing analysis of 18 Mb entire human MHC class I region. Immunol Rev 167:193-199
150. Yabuki K, Mizuki, Ota M et al (1999) Association of MICA gene and HLA B*5101 with Behcet's disease in Greece. Invest Ophthalmol Vis Sci 40:1921-1926
151. Gonzales-Escribano MF, Rodriguez MR, Aguilar F, Alvarez A, Sanchez-Roman J, Nunez-Roldan A (1999) Lack of association of MICA transmembrane region polymorphism and Behcet's disease in Spain. Tissue Antigens 54:278-281
152. Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL (1994) NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med 180:534-543
153. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M (1994) NK3-specific natural killer cells are selectively inhibited by BW4-positive HLA alleles with isoleucine 80. J Exp Med 180:1235-1242
154. Lanier LL (1998) NK cell receptors. Annu Rev Immunol 16:359-395
155. Mingari MC, Moretta A, Moretta L (1998) Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T cell responses. View Point Immunol Today 19:153-157
156. Wildner G, Thurau SR (1994) Cross reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: a clue to a major histocompatibility complex association with autoimmune disease. Eur J Immunol 24:2479-2585
157. Thurau SR, Diedrichs-Mohring M, Fricke H, Arbogast S, Wildner G (1997) Molecular mimicry as a therapeutic approach for an autoimmune disease: oral treatment of uveitis patients with an MHC-peptide cross reactive with autoantigen-first results. Immunol Lett 57:193-201
158. Kurhan-Yuvuz S, Direskeneli H, Bozkurt N et al (2000) Anti-MHC autoimmunity in Behcet's disease: T cell responses to an HLA-B derived peptide cross reactive with retinal-S antigen in patients with uveitis. Clin Exp Immunol 120:162-166
159. Chicz KM, Urban RG, Gorga JC et al (1993) Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178:27-47
160. Mayer L (2000) Oral tolerance: new approaches, new problems. Immunology 94:1-8
161. Weinberg Mor F, Cohen IR (2002) Identification of alpha-tropomycin as a target self-antigen in Behcet's syndrome. Eur J Immunol 32:356-365
162. Wacker WB, Donoso LA, Kalsow CM et al (1977) Experimental allergic uveitis. Isolation, characterization and localization of soluble uveitopathogenic antigen from bovine retina. J Immunol 119:1949-1958
163. Pfisker C, Chambre M, Plouet J et al (1986) Retinal S antigen identified as 48k protein regulating light dependent photodiesterase in rods. Science 228:891-893
164. Donoso LA, Merryman CF, Shinobora T et al (1993) Presence of multiple immunogenic sites in Lewis rat. J Autoimmun 6:589-599
165. Gregerson DS, Merryman CS, Obritsch WF et al (1990) Identification of a potent new pathogenic site in human retinal S-antigen which induces experimental uveoretinitis in Lewis rats. Cell Immunol 128:209-219
166. Faure JP, Kozak Y (1981) Cellular and humeral reactions to retinal antigens. Specific suppression of experimental uveoretinitis. In: Helmsen RJ, Suran A, Gery T, Nussenblatt (eds) JRL Press, Washington, pp 33-48
167. Yamamoto JH, Minami M, Inaba G, Masuda K, Mochizuki M (1993) Cellular auto-immunity specific antigens in patients with Behcet's disease. Br J Ophthalmol 77:584-589
168. Nussenblatt RB, Gery I, Weiner HL et al (1997) Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized trial. Am J Ophthalmol 12:583-592
169. Nussenblatt RB, Whitcup SM, de Smet MD et al (1996) Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Ann NY Acad Sci 778:325-337
170. Thurau SR, Caspi RR, Chan CC, Weiner HL, Nussenblatt RB (1991) Immunologic suppression of experimental autoimmune uveitis. Fortschr Ophthalmol 88:404-407
171. Nussenblatt RB, Caspi RR, Mahdi R, Chan CC, Roberge F, Lider O, Weiner HL (1990) Inhibition of S-antigen experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J Immunol 144:1689-1695
172. Lehner T (1969) Characterization of mucosal antibodies in recurrent apthons ulceration and Behcet's syndrome. Arch Oral Biol 14:843
173. Michealson JC (ed) (1988) The text book of the fundus of the eye, 3rd edn. Churchill Livingstone, Edinburgh, pp 701-703
174. Michelson JB (1993) Diffuse uveitis. Ophthalmol Clin North Am 6:51-67
175. Aygunduz M, Bavbek N, Ozturk M, Kaftan O, Kosar A, Kirazli S (2002) Serum 2-microglobulin reflects disease activity in BD. Rheumatol Int 22:5-8
176. Ben-Jonathan I, Mershon JL, Allen DL, Steinmetz OW (1996) Extrapituitary prolactin: distribution, regulation, functions and clinical aspect. Endocr Rev 17:639-669
177. Chikanza IC, Pterou P, Chrousus G, Kingsley G, Panayi GS (1993) Excessive and dysregulated secretion of prolaction in rheumatoid arthritis. Immunopathogenetic and therapeutic implications. Br J Rheumatol 32:445-448
178. Walker SE, Allen SH, Hoffman RW, McMurray RW (1995) Prolactin: a stimulator of disease activity in systemic lupus erythematosus. Lupus 4:3-9
179. Houman MH, Fkih M, Ghorbel B, Lamloum M, Mbazaa R, Miled M (1998) Prolactin level in Behcet's disease. Abstract of the 8th International Congress on Behcet's disease, Athens, p 50
180. Keser G, Oksel F, Ozgen G, Aksu K, Doganavsargil E (1999) Serum prolactin in Behcet's syndrome. Clin Rheumatol 18:351-352
181. Keser G, Oksel F, Aksu et al (2000) Serum neopterin in Behcet's syndrome (Letter). Clin Rheumatol 18:328-329
182. Erken E, Soy M, Canataroglu A, Gunesacar R, Ozbek S (1998) Serum neopterin and interferon gamma level in Behcet's disease. Abstract of the 8th International Congress on Behcet's disease, Athens, p 54
183. Huber C, Batchelor JR, Fuchs D et al (1984) Immune response associated production of neopterin. Release from macrophages primarily under control of interferon gamma. J Exp Med 160:310-316
184. Gamble CN, Weisner KB, Shapiro RF, Boyer WJ (1979) The immune complex pathogenesis of glomerulonephritis and pulmonary vasculitis in Behcet's disease. Am J Med 66:1031-1039
185. Lehner T, Welsh KI, Batchelor JR (1982) The relationship of HLA-B and DR phenotypes to Behcet's syndrome, recurrent oral ulceration and the class of immune complexes. Immunology 47:581-587
186. Gupta RC, O'Duffy JD, McDuffie FC, Meurer M, Jordan RE (1978) Circulating immune complexes in active Behcet's disease. Clin Exp Immunol 34:213-218
187. Gupta RC, O'Duffy JD, McGuggie FC (1977) Circulating immune complexes in active Behcet's disease. Arthritis Rheum 30:250-253
188. Kwon OH, Kim H, Kim DS et al (1991) Relationship of circulating immune complex levels with clinical activity in Behcet's syndrome. In: O'Duffy JD, Kokmen E (eds) Behcet's disease. Basic and clinical aspects. Dekker, New York, pp 355-360
189. Kevinsky RJ, Lehner T (1978) Circulating immune complex in the recurrent oral ulceration and Behcet's syndrome. Clin Exp Immunol 32:193-198
190. Burton-Kee JE, Mobray JF, Lehner T (1981) Different cross-reacting circulating immune complexes in Behcet's syndrome and recurrent oral ulcers. J Lab Clin Med 97:208-211
191. Ozoran K, Duzgun N, Tutkak H, Gurler A, Tokgoz G (1996) Fibronectin and circulating immune complexes in Behcet's disease. Rheumatol Int 15:221-224
192. Nussenblatt RB, Palestine AG, Chan CC, Mochizuki M, Yanci K (1985) Effectiveness of cyclosporin therapy for Behcet's disease. Arthritis Rheum 28:271-278
193. Valesini G, Picardo M, Pastore R et al (1981) Circulating immune complexes in Behcet's syndrome: purification, characterization and cross reactivity studies. Clin Exp Immunol 44:52-57
194. Nazzaro P (1966) Cutaneous manifestations in Behcet's disease. In: Monacelli M, Nazzaro P (eds) International symposium on Behcet's disease. Karger, Basel, pp 15-41
195. Jorizzo JL, Solomon AR, Zanolli MD, Leshin B (1988) Neutrophilic vascular reactions. J Am Acad Dermatol 19:983-1005
196. Jorizzo JL, Zanolli MD, Hall RP, Pisko EJ, Shar GG, Bass DA, Gammon WR (1991) Immune complex/neutrophil-mediated vessel damage in Behcet's disease: preliminary data on further studies. In: O'Duffy JD, Kokmen (eds) Behcet's disease. Basic and clinial aspects. Dekker, New York, pp 513-521
197. Sunakawa M, Okinaki S (1988) Fibrinopeptide A and fibrinopeptide B beta 15:42 patients with Behcet's disease. Metab Pediatr Syst Ophthalmol 11:147-148
198. Hull RG, Harris E, Gharavi A et al (1984) Anticardiolipin antibodies: occurrence in Behcet's syndrome. Ann Rheum Dis 43:746-748
199. Zouboulis CC, Buttner R, Tebbe B, Orfanos CE (1993) Anticardiolipin antibodies in Adamantiades-Behcet's syndrome. Br J Dermatol 128:281-284
200. Mader R, Ziv M, Adawi M, Mader R, Levi I (1999) Thrombophilic factors and their relation to thrombooembolic and other clinical manifestations in Behcet's disease. J Rheumatol 26:2404-2408
201. Direskeneli H, Keser G, D'Cruz D et al (1995) Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behcet's disease. Clin Rheumatol 14:55-61
202. Hughes JR, Davies JA (1998) Anticardiolipin antibodies in clinical conditions associated with a risk of thrombotic events. Thromb Res 89:101-106
203. Eftimiou J, Cambridge G, Harris EN et al (1986) Anticardiolipin antibodies and vascular complications in Behcet's syndrome. In: Lehner T, Barnes G (eds) Recent advances in Behcet's disease. Royal Society of Medicine Services, London
204. Bergman R, Lorber M, Lehner M et al (1996) Anticardiolipin antibodies in Behcet's disease. J Dermatol 17:164-167
205. Aydintug AO, Tokgoz G, Cruz D et al (1993) Antibodies to endothelial cells in patients with Behcet's disease. Clin Immunol Immunopathol 67:157-162
206. Sakane T (1991) Role of immunological abnormalities in the pathoetiology of Behcet's disease. In: O'Duffy JD, Kokmen E (eds) Behcet's disease. Basic and clinical aspects. Dekker, New York, pp 478-485
207. Abdulla YH, Lehner T (1979) The effects of immune complexes on chemotaxis in Behcet's syndrome and recurrent oral ulcers. In: Lehner T, Barnes CG (eds) Behcet's syndrome. Academic Press, London, pp 55-75
208. Fordhan JV, Davies PG, Kirk A, Currey HL (1982) Polymorphonuclear function in Behcet's syndrome. Ann Rheum Dis 41:421-425
209. Wilkinson PC (1986) Comments on enhanced leukocyte locomotion in Behcet's disease. In: Lehner T, Barnes CG (eds) Advances in Behcet's disease. International Congress and Symposium Series, no 103, Royal Society of Medicine Services, London, pp 97-98
210. Tuzun B, Tuzun Y, Mat C et al (1999) Neutrophil chemotaxis in Behcet's syndrome. Ann Rheum Dis 58:658
211. Sakane T, Suzuki N, Nagafuchi H (1997) Etiopathology of Behcet's disease: immunological aspects. Yonsei Med J 38:350-358
212. Takeno M, Kariyone A, Yamashita N et al (1995) Excessive function of peripheral blood neutrophils from patients with Behcet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 38:426-433
213. Sensi A, Gavioli R, Spisani S et al (1991) HLA B51 antigen association with neutrophil hyperactivity. Dis Markers 9:327-331
214. Carletto A, Pacor ML, Biasi D, Cramashi P, Zeminian S, Bellavite P, Bambara LM (1997) Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Behcet's disease. J Rheumatol 24:1332-1336
215. Sahin S, Akoglu T, Direskeneli H, Sen LS, Lawrence R (1996) Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behcet's disease. Ann Rheum 55:128-133
216. Jorizzo JL, Schmalsteig FC, Solomon AR, Taylor RS, Carallo T (1986) Studies of circulating immune complexes, neutrophils and effects of oral colchicine or thalidomide in Behcet's disease. In: Lehner T, Barnes CG (eds) Recent advances in Behcet's disease. Royal Society of Medicine Services, London, pp 88-96
217. Zimmerman GA, Prescott SM, McIntyre TM (1992) Endothelial cell interactions with granulocytes: tethering and signaling molecules. Immunol Today 13:93-100
218. Niwa Y, Miyake S, Sakane T et al (1982) Auto-oxidative damage in Behcet's disease - endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 49:247-255
219. Hunt SW, Harris ES, Kellerman SA et al (1996) T lymphocyte interaction with endothelium and extracellular matrix. Crit Rev Oral Biol Med 7:59-86
220. Wakefield D, McCluskey P, Palladinetti P (1992) Distribution of lymphocytes and adhesion molecules in iris biopsy specimens from patients with uveitis. Arch Ophthalmol 110:121-125
221. Whitcup SM, Chan CC, Li Q et al (1992) Expression of cell adhesion molecules in posterior uveitis. Arch Ophthalmol 110:662-666
222. Le Heig E, Kuijpers RWAM, Baarsma SG, Kijlstra A, Weiden M, Mooy CM (1998) Adhesion molecules in iris biopsy specimens in patients with uveitis. Br J Ophthalmol 82:432-437
223. Ager A, Callard R, Exine S et al (1996) Lymphocyte receptors at a glance. Immunol Today 17:25
224. Whitcup SM, Hikita M, Shirao M et al (1995) Monoclonal antibodies against CD54 (ICAM-1) and CDIIa (LFA-1) prevent and inhibit endotoxin-induced uveitis. Exp Eye Res 60:597-601
225. Whitcup SM, DeBarge LR, Rosen H, Nussenblatt RB, Chan CC (1993) Monoclonal antibody against CDIIb/CD18 inhibits endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 4:673-681
226. Bocher M, Metz CN, Calandra T et al (1996) An essential regulatory role for migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A 93:7849-7854
227. Kitaichi N, Kotake S, Sasamoto Y (1999) Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis. Invest Ophthalmol Vis Sci 40:247-250
228. Sayinalp N, Ozcebe OT, Ozdemir O, Hanznedaroglu IC, Kirazli S (1996) Cytokines in Behcet's disease. J Rheumatol 23:321-322
229. Ohno S, Kato F, Matsuda H, Fujii N, Minagawa T (1982) Detection of gamma interferon in the sera of patients with Behcet's disease. Infect Immun 36:202-208
230. Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM (1997) Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behcet's disease: soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 24:128-132
231. Kaneko F, Takahashi Y, Muramatsu Y et al (1985) Immunological studies on aphthous ulcer and erythema nodosum-like eruptions in Behcet's disease. Br J Dermatol 113:303-312
232. Vitale AT, Rodriguez A, Foster SC (1996) Low-dose cyclosporin A therapy in treating chronic non-infectious uveitis. Ophthalmology 103:365-374
233. Hirohata S, Oka H, Mizushima Y (1992) Streptococcal-related antigens stimulate production of IL6 and interferon gamma by T cells from patients with Behcet's disease. Cell Immunol 140:410-419
234. Hirohata S, Hashimoto T, Oka H et al (1993) Abnormal T cell responses to bacterial antigens in patients with Behcet's disease. In: Godeau P, Wechsler B (eds). Behcet's disease. Elsevier, Amsterdam, pp 69-72
235. Shi J, Cinek T, Truitt KE et al (1997) Wartmannin, a phosphatidylinositol 3-kinase inhibitor, block antigen-mediated, but not CD3 monoclonal antibody-induced, activation of murine CD4+ T cells. J Immunol 158:4688-4695
236. Hirohata S, Hashimoto T (1998) Abnormal T cell responses to bacterial superantigens in Behcet's disease (BD). Clin Exp Immunol 112:317-321
237. Demiralp EE, Direskeneli H, Sahin S, Karsli F, Ergun T, Fresko I, Akoglu T (1996) Increased CD4+CD16+, CD4+CD56+ and CD8+CDIIb T lymphocytes in Behcet's disease (Abstract). Rev Rhum 63:530
238. Kahan A, Hamzaoui K, Ayed K (1992) Abnormalities of T lymphocyte subsets in Behcet's disease demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies. J Rheumatol 19:742-746
239. Yamashita N, Kaneoka H, Kaneko S et al (1997) Role of gamma delta T lymphocytes in the development of Behcet's disease. Clin Exp Immunol 107:241-247
240. Yato H, Matsumoto Y (1999) CD56 T cells in the peripheral blood of uveitis. Br J Ophthalmol 83:1386-1388
241. Freydottir J, Lan S-H, Forture F (1999) gamma delta cells in Behcet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 118:451-457
242. Fortune F, Walker J, Lehner T (1990) The expression of gamma delta T cell receptor and the prevalence of primed, activated IgA-bound T cells in Behcet's syndrome. Clin Exp Immunol 82:326-332
243. Demiralp EE, Direskeneli H, Ergun T, Fresko I, Akoglu T (1999) Increased CD4+, CD16+ and CD4+CD56+ T cell subsets in Behcet's disease. Rheumatol Int 19:23-26
244. Chien Y-H, Jores R, Crowley MP (1996) Recognition by gamma/delta T cells. Annu Rev Immunol 14:511-532
245. Porcelli SA, Morita CT, Modlin A (1996) T cell recognition of non-peptide antigens. Curr Opin Immunol 8:510-516
246. Salgame P, Abrams IS, Clayberger C et al (1991) Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cells clones. Science 254:279-282
247. Kemeny D, Noble A, Holmes B, Diaz-Sanches D (1994) Immune regulation: A new role for the CD8+ T cell. Immunol Today 15:107-110
248. Powne T, Coffman RL (1993) Cytokine regulation of T cell function: potential for therapeutic intervention. Immunol Today 14:271-274
249. Abbas A, Murphy K, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383:787-793
250. Raziuddin S, Al-Dalaan A, Bahari S, Sirag AK, Al-Sedairy S (1998) Divergent cytokine production profile in Behcet's disease: altered Th1-Th2 cell cytokine pattern. J Rheumatol 25:329-333
251. Frassanito MA, Dammacco R, Cafforio P, Dammacco F (1999) Th1 polarization of the immune response in Behcet's disease. A putative pathogenetic role of interleukin 12. Arthritis Rheum 42:1967-1974
252. Romagnani S (1995) Biology of human Th1 and Th2 cells. J Clin Immunol 15:12-29
253. Mosman TR, Coffman RL (1987) Th2 and Th2 cells: different pattern of lymphokine secretion leads to different functional properties. Annu Rev Immunol 7:145-173
254. Sakane T, Suzuki N, Ueda Y et al (1986) Analysis of interleukin-2 activity in patients with Behcet's disease. Ability of T-cells to respond to interleukin-2. Arthritis Rheum 29:371-378
255. Sakane T, Kotani H, Takada S et al (1982) Functional aberration of T cell subsets in patients with Behcet's disease. Arthritis Rheum 25:1343-1351
256. Takeno M, Nogafuchi H, Suzuki N, Matsuda T, Sakane T (2001) Frequency of IL-12 receptor-bearing T cells is a simple marker to monitor the disease activity in Behcet's disease. Arthritis Rheum 44 S1741
257. Suzuki N, Sakane T, Tsunematsu T (1986) Abnormal B cell function in patients with Behcet's disease. Arthritis Rheum 29:212-219
258. Eksioglu-Demiralp E, Kibaroglu A, Direskeneli H et al (1999) Phenotypic characteristics of B cells in Behcet's disease. Increased activity in B cell subsets. J Rheumatol 26:826-832
259. Direskeneli H, Hasan A, Shinnick T et al (1996) Recognition of B-cell epitopes of the 65 kDa HSP in Behcet's disease. Scand J Immunol 43:464-471
260. Tsci B, Direskeneli H, Serdaroglu P, Akman-Demir G, Eraksoy M, Saruhan-Direskeneli G (1998) Humeral immune response to mycobacterial heat shock protein (hsp) 65 in the cerebrospinal fluid of neuro-Behcet's patients. Clin Exp Immunol 113:100-104
261. Yazici H, Akoglu T (1999) Phenotypic characteristics of B cells in Behcet's disease: increased activity of B cells subsets. J Rheumatol 26:826-832
262. Yazici H (1997) The place of Behcet's syndrome among the autoimmune diseases. Intern Rev Immunol 14:1-10
263. Marquant JL, Snyderman R, Uppenheim JJ (1973) Depression of lymphocyte transformation and exacerbation of Behcet's syndrome by ingestion of English walnuts. Cell Immunol 9:263
264. Nussenblatt RB, Whitcup SM, Palestine AG (eds) (1996) Fundamentals and clinical practice, 2nd edn. Mosby Year Book, St Louis, pp 334-353
265. Inomata H, Kohno T, Rao NA et al (1993) Vasculitis and intraocular neovascularization in Behcet's disease: histopathology of the early and late advanced stages. In: Demouchamps JP, Verougstraete C, Caspers-Velu L et al (eds) Proceedings of the Third International Symposium of Uveitis. Brussels, Belgium, May 24-27, 1992, Kugler, New York, pp 349-355
266. Assaad-Khalil SH (1991) Clinical, genetic, immunological and biochemical features of 180 Egyptian patients with Behcet's disease. In: O'Duffy JD, Kokmen E (eds) Behcet's disease. Basic and clinical aspects. Dekker, New York, pp 269-277
267. Main DM, Chamberlain MA (1992) Clinical differentiation of oral ulceration in Behcet's disease. Br J Rheumatol 31:767
268. Ehrlich GC (1972) Intermittent and periodic arthritis syndromes. In: Hollander JL, McCarty D (eds) Arthritis, 8th edn. Lea and Febiger, Philadelphia, p 821
269. Kaklamani V, Vaiopoulos G, Kaklamanis PG (1998) Behcet's disease. Semin Arthritis Rheum 27:197-216
270. Main DM, Chamberlain MA (1992) Clinical differentiation of oral ulceration in Behcet's disease. Br J Rheumatol 31:767
271. Ergun T, Gurbuz O, Dogusoy G, Mat C, Yazici H (1998) Histopathologic features of the spontaneous pustular lesions of Behcet's syndrome. Int Dermatol 37:194-196
272. Pinto JS, Freitas JP, Jorge JP, de Souza-Ramalho P (1991) Follow-up of sixty cases of Behcet's disease. In: O'Duffy JD, Kokmen E (eds) Behcet's disease. Basic and clinical aspect. Dekker, New York, pp 313-319
273. Kalbian VV, Challis MT (1970) Behcet's disease. Report of twelve cases with three manifesting as papilloedema. A Review. Am J Med 49:823
274. Nazzaro PO (1966) Cutaneous manifestations of Behcet's disease and histological findings. International Symposium on Behcet's Disease (Rome) 1965. Karger, New York, p 15
275. Magro CM, Crowson AN (1995) Cutaneous manifestations of Behcet's disease. Int J Dermatol 34:159
276. King R, Crowson AN, Murray E, Magro CM (1992) Acral purpuric papulonodular lesions as a manifestation of Behcet's disease. Int J Dermatol 31:645
277. Oguz O, Serdarglu S, Turzin Y et al (1992) Acute febrile neutrophilic dermatosis (Sweet's syndrome) associated with Behcet's disease. Int J Dermatol 19:402
278. Keinbaum S, Zouboulis CC, Waibel M, Orfanes CE (1993) Chemotactic neutrophilic vasculitis. A new histopathologic pattern of vasculitis found in mucocutaneous lesions of patients with Adamantiades-Behcet's disease. In: Godeau P, Wechsler B (eds) Behcet's disease. Elsevier, New York, pp 337-341
279. Takeda U, Kureda K, Shinkai H (1999) Encapsulated necrosis associated with Behcet's disease. J Dermatol 26:522-526
280. Mat MC, Nazarbaghi M, Tuzun Y et al (1998) Wound healing in Behcet's syndrome. Int J Dermatol 37:120-123
281. Yazici H, Fresko I, Hamuryudan V et al (1999) Behcet's syndrome. The Cerraphasa experience. Members of the Behcet's Syndrome Research Centre. Adv Exp Med Biol 455:135-140
282. Curth HO (1946) Recurrent genito-urinary aphthosis with hypopyon (Behcet's syndrome). Arch Dermatol 54:179-196
283. Curth HO (1946) Behcet's syndrome, abortive form (?) "recurrent ulcerations". Arch Dermatol 54:4881-4883
284. Hewitt J, Escanade J-P, Manesse S (1977) Revision des criteres diagnostique du syndrome de Behcet. Presse Med 79:901-908
285. Hewitt J, Escanade J-P, Lauret PH, Pearlmuter L (1996) Critere de prevision du syndrome de Behcet. Bull Soc Franc Syph 76:565-568
286. Pickering MC, Haskard DO (2000) Behcet's syndrome. J Coll Physicians Lond 34:169-177
287. Cakir N, Yazici H, Chamberlain MA et al (1991) Response to intradermal injection of monosodium urate crystals in Behcet's syndrome. Ann Rheum Dis 50:634-636
288. Inaba G (1982) Behcet's disease. Pathogenetic mechanisms and clinical features. Medical Research Foundation, Tokyo
289. Friedman-Birnbaum R, Bergman R, Aizen E (1990) Sensitivity and specificity of pathergy results in Israeli patients with Behcet's disease. Cutis 45:261-264
290. Davies PG, Fordham JN, Kirwan JR, Barnes CG, Dinnings WJ (1984) The pathergy test and Behcet's syndrome in Britain. Ann Rheum Dis 43:70-73
291. Yazici H, Chamberlain MA, Tuzun Y, Yurdakul S, Mufruoglu A (1984) A comparative study of the pathergy reaction among Turkish and British patients with Behcet's disease. Ann Rheum Dis 43:74-75
292. Dilsen N, Konice M, Ara O et al (1993) Comparative study of the skin pathergy with blunt and sharp needles in Behcet's disease. Confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis 52:823-825
293. Fresko I, Yazici H, Bayramicli M, Yurdakul S, Mat C (1993) Effect of surgical cleaning of skin on pathergy phenomenon in Behcet's syndrome. Ann Rheum Dis 52:619-620
294. O'Duffy JD (1994) Behcet's disease. Curr Opin Rheumatol 6:39-43
295. Budak-Aldogan T, Demircay Z, Alpdogan O et al (1997) Behcet's disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behcet's symptoms. Ann Hematol 74:45-48
296. Budak-Alpdogan T, Alpdogan O, Demicroy Z et al (1996) Positive skin pathergy in patients with chronic myelogenous leukemia (abstract). Rev Rhum 63:53
297. Pivetti-Pezzi P, Accorrinti M, Pirraglia M, Priori R, Valesina G (1997) Interferon alpha for ocular Behcet's disease. Acta Ophthalmol Scand 75:720-722
298. Budak-Alpdogan T, Demicroy Z, Alpdogan O et al (1998) Skin hyperactivity of Behcet's patients (pathergy reaction) is also positive in interferon alpha treated chronic myelogenous leukemia patients, indicating similarly altered neutrophil function in both disorders. Br J Rheumatol 37:1148-1151
299. Mizushima Y (1986) Chemotaxis and phagocytosis of leukocytes in Behcet's disease. An overview. In: Lehner T, Barnes CG (eds) Recent advances in Behcet's disease. Royal Society of Medicine Services, London, pp 85-87
300. Bang D, Honma T, Saito T et al (1988) Ultra-structure of vascular changes in cutaneous manifestations of Behcet's disease. Acta Derm Venereol (Stockh) 63:33-40
301. Gul A, Esin S, Dilsen N, Konice M, Wizgell H, Biberfeld P (1995) Immunohistology of skin pathergy reaction in Behcet's disease. Br J Dermatol 132:901-907
302. Barker JNWN, Ophir J, MacDonald DM (1987) Keratinocyte HLA-DR expression: the relationship to dermal lymphocytic infiltration. Clin Exp Dermatol 12:397-399
303. Griffiths CEM, Voorhees JJ, Nickoloff BJ (1989) Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 92:746-750
304. Nickoloff BJ (1988) Role of interferon-gamma in cutaneous trafficking of lymphocytes with emphasis on molecular and cellular adhesion events. Arch Dermatol 124:1835-1843
305. Schenius A, Klareskog L, Forsum U (1982) In situ identification of T lymphocyte subsets and HLA-DR expressing cells in the human skin tuberculin reaction. Clin Exp Immunol 49:325-330
306. Poulter LW, Lehner T (1989) Immunohistology of oral lesions from patients with recurrent oral ulcers and Behcet's syndrome. Clin Exp Immunol 78:189-195
307. Kaneko F, Takahashi Y, Muramatsu Y et al (1989) Immunological studies on aphthous ulcer and erythema nodosum-like eruptions in Behcet's disease. Br J Dermatol 113:303-312
308. Celenligil H, Kansu E, Ruacan S et al (1991) Characterization of peripheral blood lymphocytes and immunohistological analysis of oral ulcers in Behcet's disease. In: O'Duffy JD, Kokmen E (eds) Behcet's disease. Basic and clinical aspects. Dekker. New York, pp 487-495
309. Braley AE (1958) A case of Behcet's disease. Trans Am Acad Ophthalmol Otolaryngol 62:712-715
310. Demiraglu H, Barista I, Dandar S (1997) Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey. Ophthalmology 104:701-705
311. Mamo JG (1970) The rate of visual loss in Behcet's disease. Arch Ophthalmol 84:451-452
312. Imai Y (1971) Studies on prognosis and symptoms of Behcet's disease in long-term observations. Jpn J Clin Ophthalmol 25:665-694
313. Barra C, Belfort RJr, Abreu MT et al (1991) Behcet's disease in Brazil - a review of 49 cases with emphasis on ophthalmic manifestations. Jpn J Ophthalmol 35:339-346
314. Colvard DM, Robertson DM, O'Duffy DJ (1977) The ocular manifestations of Behcet's disease. Arch Ophthalmol 95:1813
315. Oshima Y, Shimizu T, Yokohari R et al (1963) Clinical studies on Behcet's syndrome. Ann Rheum Dis 22:36
316. Lang BA, Laxer RM, Thorner P, Greenberg M, Sylverman ED (1990) Pediatric onset of Behcet's syndrome with myositis: case report and literature review illustrating unusual features. Arthritis Rheum 33:418-420
317. Furusawa T (1958) A clinical study on mucocutaneous ocular syndrome. Gan Rinsho Iho 52:1143-1146
318. Otmani F, Brouri M, Brouri H et al (1992) Conjunctival aphthosis, an unusual site in Behcet's syndrome. Ann Rheum Dis 51:574-575
319. Matsou T, Itami M, Nakagawa H, Nakagawa M (2002) The incidence and pathology of conjunctival ulceration in Behcet's syndrome. Br J Ophthalmol 86: 140-143
320. Zamir E, Bodaghi B, Tugal-Tutkun I et al (2003) Conjunctival ulcers in BD. Ophthalmology 110:1137-1141
321. Eichhorn A, Kirch W (1998) Sicca symptoms and hearing loss in Behcet's syndrome. Dtsch Med Wochenschr 123:663-666
322. Colvard DM, Robertson DM, O'Duffy JD (1977) The ocular manifestations of Behcet's disease. Arch Ophthalmol 95:1813
323. Ben-Ezra D, Nussenblatt R (1978) Ocular manifestations of Behcet's disease. J Oral Pathol 7:431
324. Ikui H, Nishio T, Tomita I et al (1959) Histopathological studies on eye balls of Behcet's disease: report of five cases. Jpn J Clin Ophthalmol 13:409-420
325. Inomata H, Yoshikawa H, Rao NA (2003) Phacoanaphylaxis in Behcet's disease. A clinicopathologic and immunohistochemical study. Ophthalmology 110:1942-1945
326. Gartner J (1973) Electron microscopic observation of a gap at the junction of the ciliary epithelium with the retina in a human eye. Invest Ophthalmol 12:623-628
327. Kaba F, el-Baba F, Green WR (1987) Uveal neovascularization at the ora serrata and pars plana. Ann Ophthalmol 19:85-90
328. Green WR (1996) Behcet's disease. In: Spencer WH (ed) Ophthalmic pathology: an atlas and text book, 4th edn. Saunders, Philadelphia, pp 1224-1228
329. Gul A, Ozbek U, Ozturk C, Inanc M, Koneci M, Ozcelik T (1996) Coagulation Factor V gene mutation increases the risk of venous thrombosis in Behcet's disease. Br J Rheumatol 35:1178-1180
330. Movioglu H (1958) Behcet's recurrent disease: analytical review of the literature. Mo Med 55:1209
331. Mishima H, Masuda K, Shimasa S et al (1985) Plasminogen activator levels in patients with Behcet's syndrome. Arch Ophthalmol 103:935-936
332. Malukiewicz-Wisniewska G (1998) Fibrinolytic system and a central retinal vein thrombosis Klin Oczna 100:175-178
333. Matsuda T, Kaneko K, Hoshi K (1986) Platelet function in Behcet's disease. In: Lehner T, Barnes CG (eds) Recent advances in Behcet's disease. Royal College of Medicine, London, 103:133-137
334. Kirch W, Hutt HJ, Duhrsen U (1986) Platelet function in patients with Behcet's syndrome and in healthy subjects. In: Lehner T, Barnes CG (eds) Recent advances in Behcet's disease. Royal College of Medicine, London, 103:139-143
335. Zoller B, Dahlback B (1994) Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 343:1536-1538
336. Dertina RM, Rosendaal FR (1998) Venous thrombosis: the interaction of genes and environment. N Engl J Med 338:1840-1841
337. Mammo L, Al-Dallan A, Bahabri SS, Saour JN (1997) Association of factor V Leiden with Behcet's disease. J Rheumatol 24:2196-2198
338. Oner AF, Gurgey A, Gurler A, Mesci L (1998) Factor V Leiden mutation in patients with Behcet's disease. J Rheumatol 25:496-498
339. Verity DH, Vaughan RW, Madanat W et al (1999) Factor V Leiden mutation is associated with ocular involvement in Behcet's disease. Am J Ophthalmol 28:352-356
340. Uslu T, Erem C, Tosun M, Deger O (1997) Plasma endothelin-1 levels in Behcet's disease. Clin Rheumatol 16:59-61
341. Matsuo T, Sato Y, Shiraga F, Shiragami C, Tsuchida Y (1999) Choroidal abnormalities in Behcet's disease observed by simultaneous indocyanine green and fluorescein angiography with scanning laser ophthalmoscopy. Ophthalmology 106:295-300
342. Matsuo J, Ojima M, Kumashiro O et al (1982) Fluorescein angiography disorders and optic disk in Behcet's disease. In: Inaba G (ed) Behcet's disease. Pathogenetic mechanism and clinical features. University of Tokyo Press, Tokyo, pp 161-170
343. Charteries DG, Champ C, Rosenthal AR, Lightman SL (1992) Behcet's activated T lymphocytes in retinal vasculitis. Br J Ophthalmol 76:499-501
344. Charteries DG, Barton K, McCartney ACE et al (1992) CD4 lymphocytes involvement in ocular Behcet's disease. Autoimmunity 12:201-206
345. Yazici H, Yurdakul S, Hamuryudan V (2001) Behcet's disease (review). Curr Opin Rheumatol 13:18-22
346. Schirmer M, Calamia KT, Direskeneli H (2001) A comprehensive report on the latest get together of most of the current experts on BD. J Rheumatol 28:636-639
347. Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complications in Behcet's syndrome. Brain 122:2183-2194
348. Dilsen N, Konice K, Aral O, Ocal L, Inanc M, Gul A (1993) Risk factors for vital organ involvement in Behcet's disease. In: Godeau P, Wechsler B (eds) Behcet's disease. Elsevier, New York, pp 165-169
349. O'Duffy JD (1990) Vasculitis in BD. Rheumatol Dis Clin North Am 16:423-431
350. Pande I, Uppal SS, Kailash S, Kumar A, Mloviya AN (1995) Behcet's disease in India: a clinical, immunological, immunogenetic and outcome study. Br J Rheumatol 34:825-830
351. Moftouglu U, Yurdakul S, Yazici H et al (1986) Vascular involvement in Behcet's disease - a review of 129 cases. In: Lehner T, Barnes CG (eds) Recent advances in Behcet's disease. Royal Society of Medicine Services, London
352. Chajek T, Fairanu M (1973) Behcet's disease with superior vena cava occlusion associated with decreased fibrinolysis. BMJ 1:782
353. Tai YT, Fong PC, Ng WF et al (1991) Diffuse aortitis complicating Behcet's disease leading to severe aortic regurgitation. Cardiology 79:156-160
354. Benekli M, Gullu IH, Haznedaroglu JC (1998) Ischemic heart disease in Behcet's syndrome. Rheumatol Int 17:251
355. Masheter HC (1959) Behcet's syndrome complicated by intracranial thrombophlebitis. Proc R Soc Med 52:1039
356. Srivastava T (2000) Benign intracranial hypertension: a rare manifestation of Behcet's syndrome. J Assoc Physicians India 48:1217-1218
357. O'Duffy JD, Goldstein NP (1976) Neurologic involvement in seven patients with Behcet's disease. Am J Med 61:170
358. Hirohata S (1999) Central nervous system involvement in rheumatic diseases. Nippon Rinsho. 57:409-412
359. Kozin F, Haughton V, Bernard GE (1977) Neuro-Behcet's disease: two cases and neuroradiologic findings. Neurology 27:1148
360. Shimizu T (1971) Clinical and immunological studies on Behcet's disease. Folia Ophthalmol Jpn 22:801
361. Wolf S, Schotland DL, Phillip LL (1965) Involvement of the nervous system in Behcet's syndrome. Arch Neurol 12:315
362. Kim HB (2001) Ophthalmologic manifestations of Behcet's disease. In: Lee S, Bang D, Lee E, Sohn S (eds) Behcet's disease. A guide to its clinical understanding. Textbook and atlas. Springer, Berlin Heidelberg New York, pp 137-140
363. Akman-Demir G, Serdaroglu P, Tasci B et al (1996) Neurological involvement in Behcet's disease. Rev Rhu 63:549
364. Weiner SM, Ottz A, Schumacher M et al (2000) Neuro-Behcet's syndrome in a patient not fulfilling criteria for Behcet's disease: clinical features and value of brain imaging. Clin Rheumatol 19:231-234
365. Sakakibara R, Hattoti T, Boku K, Uchiyama T, Yamanishi T (2000) Micturitional disturbance in neuro-Behcet's syndrome. Auton Neurosci 83:86-89
366. Bietti GB, Bruna F (1966) An ophthalmic report of Behcet's disease. In: Mancelli M, Nazzaro P (eds) International Symposium on Behcet's Disease in Rome. Karger, Basel, pp 79-110
367. Evereklioglu C, Cokkeser Y, Doganay S, Er H, Kizilay A (2001) Audio-vestibular evaluation in patients with Behcet's syndrome. J Laryngol Otol 115:704-708
368. Pollak L, Luxon LM, Haskard DO (2001) Labyrinthine involvement in Behcet's syndrome. J Laryngol Otol 115:522-529
369. Hirohata SH, Kamoshita H, Taketani T (1989) Spontaneous remission in meningo-encephalitis in Behcet's disease. J Rheumatol 16:1283-1284
370. Gherardi D (1965) Neurological disorders in Behcet's syndrome. Lavaro Neuropsychiatry 37:281-288
371. Ahmed F, Bamford J, Coughle A, Chamberlain MA, Noble B (1993) Neuropsychological impairment in Behcet's disease. Rev Med Interne 14 [Suppl]:405
372. Kawai M, Hirohita S (2002) Cerebrospinal fluid beta-2 microglobulin in neuro-Behcet's syndrome. J Neurological Sci 179:132-139
373. Aygunduz M, Bavbek N, Otzturk M, Kaftan O, Kosar O, Kirazli S (2002) Serum beta-2 microglobulin reflects disease activity in Behcet's disease. Rheumatol Int 22:9-15
374. Jorizzo JL, Rogers RS (1990) Behcet's disease. J Am Acad Dermatol 23:738-741
375. Hamzaoui K, Hentati F, Hamzaoui A et al (1994) CDII/CD18 bearing lymphocytes in cerebro-spinal fluid from patients with active Behcet's disease. Clin Exp Rheumatol 12:575-577
376. Lehner T (1977) Oral ulceration and Behcet's syndrome. Progress report. Gut 18:49
377. Gharibdoost F, Davatchi F, Shahram F et al (1993) Clinical manifestations of Behcet's disease in Iran: analysis of 2176 cases. In: Godeau P, Wechsler B (eds) Behcet's disease. Elsevier, New York, pp 153-158
378. El-Ramani KM, Al-Dalaan A, Al-Balaa S, Al-Kawi MZ, Bohlega S (1993) Joint fluid analysis in Behcet's disease. In: Godeau P, Wechsler B (eds) Behcet's disease. Elsevier, New York, pp 273-282
379. Hamza M (1993) Enthesitis in Behcet's disease. In: Godeau P, Wechsler B (eds) Behcet's disease. Elsevier, New York, pp 251-253
380. Ehrlich GC (1972) Intermittent and periodic arthritic syndromes. In: Hollander JL, McCarthy D (eds) Arthritis, 8th edn. Lea and Febiger, Philadelphia. p 821
381. Moral F, Hamuryudan V, Yurdakul S, Yazici H (1995) Inefficacy of azopropazone in the acute arthritis of Behcet's syndrome: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol 13:493-495
382. Padula A, Ciancio G, Cantini F, Barozzi L, Scarano E, Niccoli L, Olivieri T (1999) Coexisting Behcet's disease and spondyloarthritis. Clin Rheumatol 18:499-500
383. Bernard GC, Heim LR (1974) Transfer factor treatment of Behcet's syndrome. J Rheumatol 1:34-39
384. Wolf RE, Fudenberg HH, Welch TM (1977) Treatment of Behcet's syndrome with transfer factor. JAMA 238:869
385. Sobel JD, Haim S, Obedeanu N et al (1977) Polymorphonuclear leukocyte function in Behcet's disease. J Clin Pathol 30:250-253
386. Sackstein R (1993) Effect of methylprednisolone administration on lymphocyte LECAM-1, CD44 and LFA-1 expression. Ann NY Acad Sci 696:417-418
387. Bach JF (1993) Immunosuppressive therapy for autoimmune diseases. Immunol Today 14:322-326
388. Fauci AS, Dale DC (1975) The effect of hydrocortisone on the kinetics of normal human lymphocytes. Blood 57:235-243
389. Haynes BF, Fauci AS (1978) The differential effect of in-vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus-derived lymphocytes. J Clin Invest 61:703-707
390. Whitcup SM, Nussenblatt RB (1993) Treatment of autoimmune uveitis. In: Allison AC, Lefferty KJ, Fliri H (eds) Ann NY Acad Sci 696:307-318
391. Hamuryudan V, Ozdogan H, Yazici H (1997) Other forms of vasculitis or pseudovasculitis. Baillieres Clin Rheumatol 16:335-355
392. Dinning WG (1981) Treatment of uveitis. Trans Ophthalmol Soc UK 101:391-393
393. Hirata ST, Matsuhara T, Saura R, Tatashi H, Hirohata K (1989) Inhibition of in vitro vascular endothelial cell proliferation and in vivo vascularization by low-dose methotrexate. Arthritis Rheum 32:1065-1073
394. Wong VG (1966) Methotrexate treatment of uveal disease. Am J Med Sci 251:149-239
395. Lazar M, Weiner MJ, Leopold IH (1969) Treatment of uveitis with methotrexate. Am J Ophthalmol 67:383
396. Rosenbaum JT (1993) Immunosuppressive therapy of uveitis. Ophthalmol Clin North Am 61:167-175
397. Morgan SL, Baggott JE, Vaughn WH et al (1994) Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind placebo-controlled trial. Ann Intern Med 121:833-841
398. Ortiz Z, Shea B, Suarez-Almazor ME et al (1998) The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta analysis of randomized controlled trials. J Rheumatol 25:36-43
399. Shiroky JB, Neville C, Esdaile JM et al (1993) Low dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 36:795-803
400. Kotter I, Durk H, Saal J et al (1996) Therapy of Behcet's disease. Ger J Ophthalmol 5:769-774
401. Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathoprine in Behcet's syndrome. N Engl J Med 322:281
402. Hamuryudan V, Ozyazgan Y, Hizli N et al (1997) Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum 40:469-474
403. Andrasch RH, Pirofsky B, Burns RB (1978) Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 96:247
404. Kennedy DT, Hayney MS, Lake KD (1996) Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 30:951-954
405. Tricoulis D (1976) Treatment of Behcet's disease with chlorambucil. Br J Ophthalmol 60:55-57
406. Mamo JG (1976) Treatment of Behcet's disease with chlorambucil. Arch Ophthalmol 94:580-583
407. O'Duffy JD, Robertson DM, Goldstein NP (1984) Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Medicine 76:75-84
408. Abdalla MJ, Bahoat NE (1973) Long-standing remission of Behcet's disease after chlorambucil therapy. Br J Ophthalmol 57:706-711
409. Tessler HH, Jennings T (1990) High-dose short term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br J Ophthalmol 74:353-357
410. Dinning WG (1981) Treatment of uveitis. Trans Ophthalmol Soc UK 101:391-393
411. Yang C, Liu J (1995) Chlorambucil therapy in sympathetic ophthalmia. Am J Ophthalmol 119:482-488
412. Cupps TR, Edgar LC, Fauci AS (1982) Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 128:2453-2457
413. Zhu LP, Cupps TR, Whalen G (1987) Selective effects of cyclophosphamide therapy on activation, proliferation and differentiation of human B cell. J Clin Invest 79:1082-1090
414. Turk JL, Parker D (1979) The effect of cyclophosphamide on the immune response. J Immunopharmacol 1:127-137
415. Wong VG (1969) Immunosuppressive therapy of ocular inflammatory diseases. Arch Ophthalmol 81:628
416. Davatchi F, Chams-Davatchi C, Akbarian M, Hatef MR, Alami Z (1987) Cyclophosphamide pulse therapy in ocular manifestations of Behcet's disease. Preliminary report. Xith European Congress of Rheumatology. Athens, June-July Abstract 431
417. Davatchi F, Shahram F, Chams et al (1991) Pulse therapy in ophthalmological manifestations of Behcet's disease. In: O'Duffy JD, Kokman E (eds) Behcet's disease. Basic and clinical aspects. Dekker, New York, pp 555-561
418. Wiederecht G, Lam E, Hung S, Martin M, Sigal N (1993) The mechanisms of action of FK506 and cyclosporin A. Ann NY Acad Sci 696:9-19
419. Flamand VD, Abramowicz M, Goldman C, Biernaux G et al (1990) Anti-CD3 antibodies induce T cells from umprimed animals to secrete IL-4 both in vitro and in vivo. J Immunol 144:2875
420. Granelli-Piperno A (1990) Lymphokine gene expression in vivo is inhibited by cyclosporin A. J Exp Med 171:533
421. Sigal NH, Dumont FJ (1992) Cyclosporin A, FK506 and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 10:519
422. Durez, Abramowicz D, Gerard C et al (1993) In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A. J Exp Med 177:551-555
423. Mochizuki M, Ikeda E, Shirao M et al (1992) Preclinical and clinical study of FK506 in uveitis. Curr Eye Res 11:87-95
424. Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin and FK506. Immunol Today 13:136-142
425. Sugi-Ikai N, Makazawa M, Nakamura S, Ohno S, Minami M (1998) Increased frequencies of interleukin-2 and interferon-gamma producing T cells in patients with active Behcet's disease. Invest Ophthalmol Vis Sci 39:996-1004
426. Nussenblatt R, Palestine A, Chan C et al (1985) Effectiveness of cyclosporin therapy for Behcet's disease. Arthritis Rheum 28:671-679
427. Towler HM, Whiting PH, Forrester JV (1990) Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation. Eye 4:514-517
428. Bielory L, Holland C, Gascon P, Frohman L (1988) Uveitis, cutaneous and neurosarcoid. Treatment with low-dose cyclosporin. Transplant Proc 20 [Suppl]:144
429. Whitcup SM, Salvo EC, Nussenblatt RB (1994) Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol 118:39-45
430. Mochizuki M, Masuda K, Sakane T et al (1993) A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 115:763-769
431. Suzuku N, Kaneco S, Ichino M, Mihara S, Wakisaka S, Sakane T (1997) In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK506): experience in patients with Behcet's disease. Arthritis Rheum 40:1157-1167
432. Tilney NL, Strom TB, Kupiec-Weglinski JW (1988) Pharmacologic and immunologic agonists and antagonists of cyclosporine. Transplant Proc 20 [Supp[3]:3
433. De Smel MD, Rubin BI, Whitcup SM, Lopez JS, Austin HA, Nussenblatt RB (1992) Combined use of cyclosporin and ketokonazole in treatment of endogenous uveitis. Am J Ophthalmol 113:687-690
434. Palestine AG, Nussenblatt RB, Gelato M (1988) Therapy for human autoimmune uveitis with low dose cyclosporin plus bromocriptine. Transplant Proc 20:131
435. Ben-Chetrit E, Levy M (1998) Does the lack of P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases? Med Hypotheses 51:377-380
436. Hijikata K, Masuda K (1978) Visual prognosis in Behcet's disease: effects of cyclosphosphamide and colchicine treatment. Jpn J Ophthalmol 22:506-511
437. Aktulga E, Altac M, Muftuoglo A et al (1980) A double blind study of colchicine in Behcet's disease. Haematologica (Budap) 65:399-402
438. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173:699-703
439. Rowland TL, McHugh SM, Deighton J, Ewan PW, Dearman RJ, Kimber I (1999) Selective down regulation of T-cell and non-T cell derived tumor necrosis factor alpha by thalidomide: comparisons with dexamethasone. Immunol Lett 68:325-333
440. D'Amato RJ, Loughman MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085
441. Hamuryudan V, Mat C, Saip S, Ozyagan Y, Siva A, Yurdakul S et al (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behcet's syndrome, a randomized double-blind, placebo-controlled trial. Ann Intern Med 128:243-250
442. Hamza M (1986) Treatment of Behcet's disease with thalidomide. Cin Rheumatol 5:365-371
443. Jorizzo JL, Sclamsteig FC, Solomon AR, Cavallo T, Taylor RS, Rudloff HB et al (1986) Thalidomide effects in Behcet's syndrome and pustular vasculitis. Arch Intern Med 146:878-881
444. Larsson H (1990) Treatment of severe colitis in Behcet's syndrome with thalidomide (GC-217). J Intern Med 228:405-407
445. Ehrlich GE (1999) Behcet's disease: an update. Comp Ther 25:216-225
446. Grispan D, Fernandez Blanco G, Aguero S (1989) Treatment of aphthae with thalidomide. J Am Acad Dermatol 20:1060-1063
447. Revuz J, Guillaume J-C, Janier M, Hans P, Marchand C (1990) Crossover study of thalidomide vs. placebo in severe recurrent aphthous stomatitis. Arch Dermatol 126:923-927
448. Hale G, Xia M-Q, Tighe HP, Dyer MJS, Waldman H (1990) The Campath-1 antigen (CD52). Tissue Antigens 35:118-127
449. Xia M-G, Hale G, Lifely MR et al (1993) Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is exceptionally good target for complement lysis. Biochemistry 293:633-640
450. Isaacs JD, Dick AD, Haynes RJ et al (1995) Monoclonal antibody therapy in intraocular inflammation using Campath-1. Br J Ophthalmol 79:1054-1055
451. Dick AD, Isaacs JD (1999) Immunomodulation of autoimmune responses with monoclonal antibodies an immunoadhesions: treatment of ocular inflammatory disease in the next millenium Br J Ophthalmol 83:1230-1234
452. Dick AD, Meyer P, James T et al (2000) Campath-1 therapy in refractory ocular inflammatory disease. Br J Ophthalmol 84:107-109
453. Dick (1995) Specific approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis. Br J Ophthalmol 93:593-598
454. Ben Ezra D, Maftzir G, Barak V (1997) Blood serum interleukin receptor antagonist in pars planitis and ocular Behcet's disease. Am J Ophthalmol 123:593-598
455. Prud'homme GJ, Lawson BR, Theofilopoulos AN (2001) Anticytokine gene therapy of autoimmune diseases. Exp Opin Biol Ther 1:359-373
456. Gossens PH, Verburg RJ, Breedveld FC (2001) Remission of Behcet's syndrome with tumor necrosis factor alpha blocking therapy. Ann Rheum Dis 60:637
457. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA (2001) Antitumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 120:995-999
458. Alpsoy E, Yilmaz E, Basaran E (1994) Interferon therapy for Behcet's disease. J Am Acad Dermatol 31:617-619
459. Tsambos D, Eichelberg D, Goos M (1986) Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon. Dermatology 278:335-336
460. Dundar S, Ozcebe OI, Ozdemir O, Kirazli S (1993) Alpha-interferon in the treatment of Behcet's disease. In: Godeau P, Wechsler B (eds) Behcet's disease. Lippincot William & Wilkins, Philadelphia, PA, pp 665-670
461. Durand M, Kaklanski G, Telle H, Saubeyrand J, Paulo F (1993) Beneficial effect of interferon alpha-2b in Behcet's disease. Arthritis Rheum 36:1025-1026
462. Gross WL (1999) New concepts in treatment protocols for systemic vasculitis. Curr Opin Rheumatol 11:41-46
463. Pivetti-Pezzi P, Accorinti M, Pirraglia MP, Priori R, Valesini G (1997) Interferon alpha for ocular Behcet's disease. Acta Ophthalmol Scand 75:720-722
464. Kotter I, Durk H, Eekstein A, Zierhut M, Fierbeck G, Saal JG (1996) Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study. Clin Exp Rheumatol 14:313-315
465. Hamuryudan V, Moral F, Yurdakul S et al (1994) Systemic interfeon alpha-2b treatment in Behcet's syndrome. J Rheumatol 21:1098-1100
466. Georgiou S, Monastirli A, Pazmatzi E, Gartaganis S, Goerz G, Tsambaos D (1998) Efficacy and safety of systemic recombinant interferon-alpha in Behcet's disease. J Intern Med 243:367-372
467. Guyer DR, Tiedeman J, Yannuzzi LA et al (1993) Interferon associated retinopathy. Arch Ophthalmol 111:350-356
468. Purvin VA (1995) Anterior ischemic retinopathy secondary to interferon. Arch Ophthalmol 113:1041-1044
469. Budak-Alpdogan T, Demircay Z, Alpdogan O et al (1997) Behcet's disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behcet's symptoms-case report. Ann Hematol 74:45-48
470. Segawa F, Shimizu Y, Saito E, Kinoshita M (1995) Behcet's disease induced by interferon therapy for chronic myelogenous leukemia. J Rheumatol 22:1183-1184
471. Tassies D, Cervantes F, Feliu E, Cabal G, Martinez-Orozco F, Rozman C (1990) Enfermedad de Behcet de inicio previo a la aparicion de leucemia mieloide cronica. Med Clin (Barc) 99:67-68
472. Mege Jl, Dilsen N, Sanguedolce V et al (1993) Overproduction of monocyte derived TNF-alpha, IL-6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subject. J Rheumatol 20:1544-1549
473. Kin HS, Yoon SK, Joo CK (2001) The expression of multiple cytokines and inducible nitirc acid synthetase in experimental melanin-induced uveitis. Ophthalmic Res 33:329-335
474. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM et al (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33:251-255
475. Smith MD, Bertouch JV, Smith AM et al (1988) The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. Clinical effects. J Rheumatol 15:229-232
476. Youssef PP, Haynes DR, Triantafillou S, Parker A, Gamble J et al (1997) Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid and synovial membrane in rheumatoid arthritis. Arthritis Rheum 40:400-408
477. Sfikakis PP, Theodosiadis PG, Katsiari P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 385:295-296
478. Rozenbaum M, Rosner I, Portnoy E (2002) Remission of Behcet's disease with TNF alpha blocking treatment. Ann Rheum Dis 61:383-384
479. Smith JR, Levinson RD, Holland GN (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Care Res 45:252-257
480. Galguneri M, Kiraz S, Ertemli I, Benekli M, Karaarslan Y, Celik I (1996) The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease: a randomized clinical trial. Arthrtis Rheum 63:554
481. Calguneri M, Ertemli I, Kiraz S, Erman M, Celik I (1996) Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease. Dermatology 192:125-128
482. Kaklamani VG, Vaiopooooulos G, Kaklamanis PG (1998) Behcet's disease. Semin Arthritis Rheum 27:197-217
483. Lavery HA, Pinkerton JHM (1985) Successful treatment of Behcet's syndrome with levamisole. Br J Dermatol 113:372-375
484. Yasui K, Ohta K, Konayashi M, Aizawa T, Komiyama A (1996) Successful treatment of Behcet's disease with pentoxifylline. Ann Intern Med 124:891-893
485. Hill HR, Augustine NH, Newton JA, Shigeoka AO, Morris E, Sacci F (1987) Correction of a developmental defect in neutrophil activation and movement. Am J Pathol 128:307-314
486. Buescher ES, Mellheran SM, Banks SM, Vadhan-Raj S (1990) Alteration of the functional effect of granulocyte-macrophage colony-stimulating factor on polymorphonuclear leukocytes by membrane-fluidizing agents. Infect Immun 58:3002-3008
487. Takeuchi A, Hashimoto T (1987) Oral prostaglandin E1, as a therapeutic modality for leg ulcers in Behcet's disease. Int J Clin Pharmacol Res 7:283-287
488. Samangooci SH, Mehiyar M, Hakim SM, Safamanesh S (1996) Clinical trial of sulphasazaline for treatment of uveitis in Behcet's disease (Abstract). Rev Rhum 63:561
489. Nussenblatt RB, Igal G, Weiner H et al (1997) Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol 123:583-592
490. Bach J-F (1997) Tolerance and uveitis. Am J Ophthalmol 123:684-687